Protagenic Therapeutics, Inc.\new (PTIX)

Import this data to Google Sheets with:

=jivedata("PTIX","financials")

Full statements spill as a table. For one cell: =jivedata("PTIX","Revenue") or =jivedata("PTIX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.

Protagenic Therapeutics, Inc.\new

PTIX • CIK 0001022899

(in thousands, except per share data)	FY 2023	FY 2024	FY 2026	TTM
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,300,032	6,922,136	3,377,946	-6,777,471

(in thousands, except per share data)	FY 2023	FY 2024	FY 2026	TTM
Assets	$4,323.369	$1,955.913	$3,650.37	$2,796.006
Liabilities	$655.252	$942.759	$1,031.479	$1,072.614
Prepaid Expense, Current	$144.025	$44.398	$33.408	$143.886
Value Added Tax Receivable, Current	—	—	$73.524	$41.523
Inventory, Net	—	—	$1.038	$1.074
Assets, Current	$4,200.037	$1,882.867	$1,542.586	$709.871
Property, Plant and Equipment, Net	$123.332	$73.046	$14.556	$6.244
Intangible Assets, Net (Excluding Goodwill)	—	—	$2,093.228	$2,079.891
Assets, Noncurrent	—	—	$2,107.784	$2,086.135
Notes Payable, Current	—	—	$1,669.921	$3,155.909
Accounts Payable, Current	—	—	$949.517	$999.69
Accrued Liabilities, Current	—	—	$81.962	$72.924
Derivative Liability, Current	—	—	$1,382.75	$544.353
Loans Payable, Current	—	—	$779.201	$840.389
Common Stock, Value, Issued	$0.444	$0.725	$0.182	$0.182
Additional Paid in Capital	$34,559.091	$37,445.495	$6,991.452	$7,058.464
Retained Earnings (Accumulated Deficit)	$-30,777.872	$-36,303.216	$-4,029.629	$-4,993.245
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	—	—	$-343.114	$-342.009
Stockholders' Equity Attributable to Parent	$3,668.117	$1,013.154	$2,618.891	$1,723.392
Preferred Stock, Shares Authorized	20,000,000	20,000,000	2,000,000	2,000,000
Preferred Stock, Shares Issued	0	0	0	0
Common Stock, Shares Authorized	100,000,000	100,000,000	100,000,000	100,000,000
Common Stock, Shares, Issued	4,435,132	7,241,443	1,810,208	1,810,208

(in thousands, except per share data)	FY 2023	FY 2024	FY 2026	TTM
Net Income (Loss) Attributable to Parent	$-5,000.497	$-5,525.344	$1,367.977	$5,461.884
Net Cash Provided by (Used in) Operating Activities	$-3,703.776	$-4,216.517	$-2,806.8	$-1,999.957
Payments to Acquire Productive Assets	$149.775	$149.775	$3.297	$3.297
Net Cash Provided by (Used in) Investing Activities	$4,775.482	$2,802.88	$629.883	$629.883
Proceeds from Notes Payable	—	—	$1,622.003	$1,622.003
Proceeds from Issuance of Common Stock	—	$1,900	$395.474	$395.474
Proceeds from Warrant Exercises	—	—	$3,949.73	$3,949.73
Proceeds from Related Party Debt	—	—	$62.347	$62.347
Net Cash Provided by (Used in) Financing Activities	—	$1,963.546	$3,873.653	$3,873.653
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	—	—	$1,696.736	$-3,446.439
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	$0.998	$0.667	$-202.089	$-83.765
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	—	—	$1,509.178	$-2,021.026
Amortization of Debt Discount (Premium)	$85.77	$85.77	$1,567.479	$1,567.479
Payments for (Proceeds from) Previous Acquisition	—	—	$-943.18	$-943.18
Share-based Payment Arrangement, Expense	—	—	$418.589	$360.474
Derivative, Gain (Loss) on Derivative, Net	—	—	$-343.399	$-343.399
Depreciation	$28.218	$50.286	$49.215	$44.956
Gain (Loss) on Extinguishment of Debt	—	—	$-1,117.778	$-1,117.778
Increase (Decrease) in Inventories	—	—	$0.026	$0.026
Increase (Decrease) in Prepaid Expense	$87.086	$-99.627	$-53.393	$8.813
Increase (Decrease) in Accounts Payable	—	—	$1,038.902	$824.063
Increase (Decrease) in Accrued Liabilities	—	—	$17.421	$-248.375

Loading financial statements…

Import this data to Google Sheets with:

=jivedata("PTIX","financials")

Full statements spill as a table. For one cell: =jivedata("PTIX","Revenue") or =jivedata("PTIX","Revenue","TTM"). Install the Jive Data add-on, then paste into a cell.